Skip to contentP
Pulse Biosciences, Inc.
P
PLSEPulse Biosciences, Inc. Q1 2024 · 10-Q
Revenue$0.00$0.00— vs Q1 2023 Net Income-$10.14M-$10.14MN/M vs Q1 2023 EPS, diluted—
Operating Income-$10,615,000N/M Operating Cash Flow-$9,780,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pulse Biosciences, Inc. · CIK 1625101 · Engraved from SEC EDGAR
Free Cash Flowderived-$9,785,000N/M ended Mar 31, 2024 · filed May 7, 2024 · 37 d after period end